Fortunato Scalera
Overview
Explore the profile of Fortunato Scalera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goette A, Hammwohner M, Bukowska A, Scalera F, Martens-Lobenhoffer J, Dobrev D, et al.
Int J Cardiol
. 2010 Oct;
154(2):141-6.
PMID: 20926145
Background: The endothelial nitric oxide synthase (eNOS) inhibitor asymmetric dimethylarginine (ADMA) is a well-established risk factor for oxidative stress, vascular dysfunction, and congestive heart failure. The aim of the present...
2.
Scalera F, Fulge B, Martens-Lobenhoffer J, Heimburg A, Bode-Boger S
Biochem Biophys Res Commun
. 2009 Oct;
390(3):703-9.
PMID: 19833096
To investigate the effect of three red wines (RWs) from different growing areas and made from different grapes on asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, in...
3.
Scalera F, Closs E, Flick E, Martens-Lobenhoffer J, Boissel J, Lendeckel U, et al.
Biochem Biophys Res Commun
. 2009 Jun;
386(4):650-5.
PMID: 19545540
We have recently shown that inhibition of nitric oxide (NO) synthesis by asymmetrical dimethylarginine (ADMA) accelerated endothelial cell (EC) senescence which was prevented by coincubation with L-arginine; however the effect...
4.
Ajtay Z, Scalera F, Cziraki A, Horvath I, Papp L, Sulyok E, et al.
Int J Mol Med
. 2009 Apr;
23(5):651-7.
PMID: 19360324
The concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is increased in patients with coronary heart disease (CHD). The potential effect of percutaneous coronary intervention (PCI)...
5.
Goette A, Wolfram O, Jentsch-Ullrich K, Martens-Lobenhoffer J, Scalera F, Lendeckel U, et al.
Int J Cardiol
. 2009 Mar;
143(3):264-70.
PMID: 19303649
Objective: Progenitor cells (PC) are thought to induce angiogenesis, and thereby, PC may help to improve ventricular performance in patients with ischemic heart disease (IHD). However, mobilization of progenitor cells...
6.
Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Tager M, Bode-Boger S
Hypertension
. 2008 Feb;
51(3):696-703.
PMID: 18250362
Telmisartan, in addition to blocking angiotensin (Ang) II type 1 receptor (AT(1)R), activates peroxisome proliferator activated receptor gamma (PPARgamma) signaling that interferes with nitric oxide (NO) system. Because aging of...
7.
Bode-Boger S, Scalera F, Ignarro L
Pharmacol Ther
. 2007 May;
114(3):295-306.
PMID: 17482266
Cardiovascular diseases (CVD) are still the most frequent cause of death in Western Europe. Pathophysiological experiments revealed in the last years that the vascular endothelium, as well as a result...
8.
Kielstein J, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al.
Stroke
. 2006 Jul;
37(8):2024-9.
PMID: 16809568
Background And Purpose: Preclinical studies have revealed that the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA), increases vascular tone in cerebral blood vessels. Marked elevations of ADMA blood levels...
9.
Scalera F, Martens-Lobenhoffer J, Tager M, Bukowska A, Lendeckel U, Bode-Boger S
Biochem Biophys Res Commun
. 2006 May;
345(3):1075-82.
PMID: 16713997
We investigated here the effect of l-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial aging. Endothelial cells were cultured in medium containing 70micromol/L arginine until fourteenth passage. ADMA, dl-homocysteine, and...
10.
Bode-Boger S, Scalera F, Kielstein J, Martens-Lobenhoffer J, Breithardt G, Fobker M, et al.
J Am Soc Nephrol
. 2006 Feb;
17(4):1128-34.
PMID: 16481412
Symmetrical dimethylarginine (SDMA) is the structural isomer of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine. Whereas the major route of asymmetric dimethylarginine elimination is the hydrolytic degradation by...